Outcomes have fallen short of expectations: CSL

CSL share price tumbles to 10-year low on back of US$5 billion asset write-off  Australian pharmaceutical and biotechnology firm, CSL, is cutting its full-year revenue and earnings forecasts following a 90-day review by interim chief executive, Gordon Naylor.   In an update to the Australian Securities Exchange (ASX), the company revealed it expects full-year revenues to fall by 2% to US$15.2 billion, with net profit